On June 18, 2020 Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, reported that it will host a webcast seminar to discuss the latest data from its HPK1 program on Thursday, June 25, from 11 a.m. to 12 p.m. ET (Press release, Nimbus Therapeutics, JUN 18, 2020, View Source [SID1234561212]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The seminar will feature presentations by Nimbus’ scientific leadership that give a brief overview of the company’s discovery pipeline and a deeper dive on data contained in the company’s poster presentation at the AACR (Free AACR Whitepaper) Virtual Annual Meeting II, June 22-24. The included data detail Nimbus’ identification of an HPK1 inhibitor with highly potent and selective anti-tumor activity in preclinical models.

If you wish to attend the live webcast, please pre-register at https://bit.ly/NimbusHPK1Seminar. A replay of the webcast will be available at this link after the event.